Metraipolis › archive › dc_ff4621bfafa2

Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy — Europe PMC PMID:41472726

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41472726
DOI: 10.3389/fimmu.2025.1713382
License (as archived): solo-consultazione
Archived: 2026-11-07T15:39:16.420Z
SHA-256 of the archived text: f61ac5f5548042cf3943e4191cf0733b47856be5e3f9fcfd0f986938a80e1ee3
Stable URL of this page: https://metraipolis.com/documento/dc_ff4621bfafa2

How to cite

Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy — Europe PMC PMID:41472726 — Europe PMC (en), https://europepmc.org/article/MED/41472726 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ff4621bfafa2 (Metraipolis archive dc_ff4621bfafa2, sha256 f61ac5f5548042cf3943e4191cf0733b47856be5e3f9fcfd0f986938a80e1ee3)

BibTeX

@misc{dcff4621bfafa2,
  title = {Leveraging beneficial microbiome-immune interactions via probiotic use in cancer immunotherapy — Europe PMC PMID:41472726},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41472726},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ff4621bfafa2; sha256 f61ac5f5548042cf3943e4191cf0733b47856be5e3f9fcfd0f986938a80e1ee3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41472726. Agents can read the archived copy with the MCP tool read_document.